GPC3 and hepatocellular carcinoma: Their clinical development in HCC and hepatoblastoma followed promising results from pre-clinical studies and mostly involves AFP, glypican-3, epithelial growth factor receptor, and HBV antigens (NCT03618381; NCT04093648) [51].